Related Experiment Video

Updated: Jul 29, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models

M Liu1, W R Bishop, L L Nielsen

  • 1Schering-Plough Research Institute, Kenilworth, New Jersey 07033-1300, USA.

Methods in Enzymology
|June 13, 2001
PubMed

Insights

Farnesyl transferase inhibitors (FTIs) like SCH 66336 show promise in preclinical cancer models. Further studies are needed to guide clinical development of these novel antitumor agents.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Farnesyl transferase inhibitors (FTIs) are a novel class of anticancer agents.
  • SCH 66336 is a lead FTI identified through in vivo evaluation.

Purpose of the Study:

  • To evaluate the preclinical efficacy of FTIs, including SCH 66336.
  • To explore the potential of FTIs as single agents and in combination therapy for various human cancers.

Main Methods:

  • In vivo evaluation of SCH 66336 and other FTIs in preclinical cancer models.
  • Assessment of FTIs as single agents and in combination with cytotoxic chemotherapy.

Main Results:

  • Preclinical studies suggest FTIs may be effective against a broad spectrum of human cancers.
  • Tumor regression was observed in some cases with FTI monotherapy.
  • Combination therapy with cytotoxic agents showed enhanced efficacy in animal models.

Conclusions:

  • FTIs, including SCH 66336, demonstrate potential as antitumor agents for diverse cancers.
  • Combination strategies may improve the clinical efficacy of FPT inhibitors.
  • Further preclinical research is crucial for guiding the clinical development of FTIs.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...